The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from the University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the promising results, including a response to treatment in all patients, with a significant proportion showing no detectable minimal residual disease (MRD) after 6 months of combination therapy. Prof. Hillmen touches on the steps going forward, such as investigating the combination in Phase III studies and eventually the aim of earlier use in the treatment timeline in order to reach MRD negativity. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.
Outstanding results from CLARITY: a new CLL combination therapy
